About NBE Therapeutics
NBE Therapeutics is a company based in Basel (Switzerland) founded in 2012 was acquired by Boehringer Ingelheim in December 2020. It operates as a HealthTech. NBE Therapeutics has raised $65.86 million across 11 funding rounds from investors including Boehringer Ingelheim, Boehringer Ingelheim Venture Fund and PPF Group. NBE Therapeutics offers products and services including Antibody-Drug Conjugates (ADCs). NBE Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Basel, Switzerland
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nbe-Therapeutics Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$65.86 M (USD)
in 11 rounds
-
Latest Funding Round
$22 M (USD), Series C
Jan 10, 2020
-
Investors
Boehringer Ingelheim
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Boehringer Ingelheim
(Dec 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NBE Therapeutics
NBE Therapeutics offers a comprehensive portfolio of products and services, including Antibody-Drug Conjugates (ADCs). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative ADCs are developed for targeted cancer treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of NBE Therapeutics
NBE Therapeutics has successfully raised a total of $65.86M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series C — $22.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series C - NBE Therapeutics | Valuation | Boehringer Ingelheim Venture Fund , PPF Group |
|
| Jun, 2018 | Amount | Series B - NBE Therapeutics | Valuation | PPF Group | |
| Jan, 2018 | Amount | Grant - NBE Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NBE Therapeutics
NBE Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Boehringer Ingelheim, Boehringer Ingelheim Venture Fund and PPF Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Founded Year | Domain | Location | |
|
PPF Group is engaged in international investment across diverse sectors.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NBE Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NBE Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nbe Therapeutics Comparisons
Competitors of NBE Therapeutics
NBE Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nbe Therapeutics
Frequently Asked Questions about NBE Therapeutics
When was NBE Therapeutics founded?
NBE Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is NBE Therapeutics located?
NBE Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Is NBE Therapeutics a funded company?
NBE Therapeutics is a funded company, having raised a total of $65.86M across 11 funding rounds to date. The company's 1st funding round was a Grant of $240.22K, raised on Jan 31, 2013.
What does NBE Therapeutics do?
NBE Therapeutics is engaged in the development of next-generation antibody-drug conjugates (ADCs) for oncology treatments. The company targets solid tumors through innovative in-house technologies, aiming to increase survival rates and improve the quality of life for cancer patients worldwide. A pipeline of ADC product candidates in various stages of development is maintained to advance clinical phases and provide selective drugs. The focus is placed on precision medicine to transform cancer care with long-lasting immune oncology effects.
Who are the top competitors of NBE Therapeutics?
NBE Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does NBE Therapeutics offer?
NBE Therapeutics offers Antibody-Drug Conjugates (ADCs).
Who are NBE Therapeutics's investors?
NBE Therapeutics has 5 investors. Key investors include Boehringer Ingelheim, Boehringer Ingelheim Venture Fund, PPF Group, Novo Holdings, and The Swiss Initiative in Systems Biology.